|
Proteintech
p gp P Gp, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/gps/P+glycoprotein+Antibody/pm42836044-105-43-46 Average 96 stars, based on 1 article reviews
p gp - by Bioz Stars,
2026-10
96/100 stars
|
Buy from Supplier |
|
MedChemExpress
p gp pump inhibitors encequidar P Gp Pump Inhibitors Encequidar, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/gps/Encequidar/10__1158_slash_1078___0432__ccr___26___2010-72-34-38 Average 92 stars, based on 1 article reviews
p gp pump inhibitors encequidar - by Bioz Stars,
2026-10
92/100 stars
|
Buy from Supplier |
|
Alomone Labs
α syn ![]() α Syn, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/gps/Guinea+Pig+Anti-Alpha-Synuclein+Antibody/pmc13626330-5-0-7 Average 94 stars, based on 1 article reviews
α syn - by Bioz Stars,
2026-10
94/100 stars
|
Buy from Supplier |
|
Alomone Labs
girk2 ![]() Girk2, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/gps/Guinea+pig+Anti-GIRK2+(Kir3%2E2)+Antibody/pm42794476-392-36-40 Average 94 stars, based on 1 article reviews
girk2 - by Bioz Stars,
2026-10
94/100 stars
|
Buy from Supplier |
|
Alomone Labs
bdnf ![]() Bdnf, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/gps/Guinea+pig+Anti-BDNF+Antibody/10__1186_slash_s13195___026___02193___3-92-71-75 Average 91 stars, based on 1 article reviews
bdnf - by Bioz Stars,
2026-10
91/100 stars
|
Buy from Supplier |
|
Alomone Labs
antibodies against girk2 ![]() Antibodies Against Girk2, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/gps/Guinea+pig+Anti-GIRK2+(Kir3%2E2)+Antibody/bio_rxiv__64898__2026__09__23__753784-434-9-13 Average 94 stars, based on 1 article reviews
antibodies against girk2 - by Bioz Stars,
2026-10
94/100 stars
|
Buy from Supplier |
|
Alomone Labs
guinea pig anti trpv1 ![]() Guinea Pig Anti Trpv1, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/gps/Guinea+pig+Anti-TRPV1+(VR1)+Antibody/pm42734091-111-7-15 Average 95 stars, based on 1 article reviews
guinea pig anti trpv1 - by Bioz Stars,
2026-10
95/100 stars
|
Buy from Supplier |
|
Alomone Labs
guinea pig ![]() Guinea Pig, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/gps/Guinea+pig+Anti-KCNQ2+Antibody/pmc13518552-409-16-19 Average 94 stars, based on 1 article reviews
guinea pig - by Bioz Stars,
2026-10
94/100 stars
|
Buy from Supplier |
|
Alomone Labs
anti connexin 43 antibody ![]() Anti Connexin 43 Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/gps/Guinea+pig+Anti-Connexin-43+Antibody/bio_rxiv__64898__2026__08__07__743611-42-0-7 Average 94 stars, based on 1 article reviews
anti connexin 43 antibody - by Bioz Stars,
2026-10
94/100 stars
|
Buy from Supplier |
Journal: PLOS One
Article Title: AZP2006 in Parkinson’s disease models: A promising new neuroprotective treatment involving lysosomal homeostasis and the Progranulin/Prosaposin complex
doi: 10.1371/journal.pone.0359269
Figure Lengend Snippet: Antibodies used for in vitro investigations.
Article Snippet:
Techniques: In Vitro
Journal: PLOS One
Article Title: AZP2006 in Parkinson’s disease models: A promising new neuroprotective treatment involving lysosomal homeostasis and the Progranulin/Prosaposin complex
doi: 10.1371/journal.pone.0359269
Figure Lengend Snippet: Body mass evolution during 35 days of daily treatment with vehicle or AZP2006 post-lesion (A). Representative IHC images TH (red)/α-syn (green)/Iba1 (purple) (B). IHC analysis shows the total number of TH(+) neurons (C), area of α-syn accumulation in TH(+) neurons (D) and the number of Iba1(+) microglia in the SNpc (E) expressed as % of sham. Raw values for sham (i.e., 100%); TH(+) neurons = 65 ± 1.6; α-syn area/TH(+) neuron = 168 ± 9.4 µm 2 ; Iba1(+) cells = 53 ± 2.8. Each bar represents the mean ± SEM, one-way ANOVA followed by Fisher’s test. ## p < 0.01 or #### p < 0.0001 from sham; **p < 0.01; ***p < 0.001 and ****p < 0.0001 from α-syn+vehicle injury, (n = 7 mice / group).
Article Snippet:
Techniques: Analysis
Journal: PLOS One
Article Title: AZP2006 in Parkinson’s disease models: A promising new neuroprotective treatment involving lysosomal homeostasis and the Progranulin/Prosaposin complex
doi: 10.1371/journal.pone.0359269
Figure Lengend Snippet: ICC analysis of cultures shows the total number of TH(+) neurons (A,E), the length of their neurite network (B,F), the area of cytoplasmic α-syn staining per TH(+) neuron (C,G) and the area of the post-synaptic marker PSD95 per TH(+) neuron (D and H), expressed as % of control (CTR). Raw values for CTR (i.e., 100%); sum TH(+) neurons per well, i.e., per biological replicate = 27 ± 1.0; neurite network = 3540 ± 127 µm; α-syn area/TH(+) neuron = 201 ± 8.9 µm 2 ; PSD95 area/TH(+) neuron = 1829 ± 105 µm 2 . Each bar represents the mean ± SEM, one-way ANOVA followed by Fisher’s test. ## p < 0.01; ### p < 0.001 or #### p < 0.0001 from CTR (control) or from anti-PGRN Ab and *p < 0.05 or ****p < 0.0001 from 6OHDA or from 6OHDA + anti-PGRN Ab; (n = 4-6 / group).
Article Snippet:
Techniques: Analysis, Staining, Marker, Control
Journal: PLOS One
Article Title: AZP2006 in Parkinson’s disease models: A promising new neuroprotective treatment involving lysosomal homeostasis and the Progranulin/Prosaposin complex
doi: 10.1371/journal.pone.0359269
Figure Lengend Snippet: ICC analysis of cultures shows the total number of TH(+) neurons (A,E), the length of their neurite network (B,F), the area of cytoplasmic α-syn per TH(+) neuron (C,G) and lysosome burden as area of LAMP2(+) vesicles per TH(+) neuron (D and H), expressed as % of control (CTR). Raw values for MPP + & Rotenone CTR (i.e., 100%); sum TH(+) neurons per well, i.e., per biological replicate = 18 ± 0.5 & 26 ± 1; neurite network = 889 ± 57 & 929 ± 24 µm; α-syn area/TH(+) neuron = 29 ± 2.1 & 28 ± 1 µm 2 ; ratio LAMP2/TH(+) = 10 ± 0.3 & 10 ± 0.5, respectively. Each bar represents the mean ± SEM, one-way ANOVA followed by Fisher’s test. #### p < 0.0001 from CTR and *p < 0.05, **p < 0.01; ***p < 0.001 or ****p < 0.0001 from MPP + or Rotenone treatment, (n = 4-6 / group).
Article Snippet:
Techniques: Analysis, Control
Journal: PLOS One
Article Title: AZP2006 in Parkinson’s disease models: A promising new neuroprotective treatment involving lysosomal homeostasis and the Progranulin/Prosaposin complex
doi: 10.1371/journal.pone.0359269
Figure Lengend Snippet: ICC analysis of cultures shows the total number of TH(+) neurons (A), the length of their neurite network (B), the area of cytoplasmic α-syn staining per neuron (C), the area of LAMP2(+) staining per TH(+) neuron (D), the α-syn accumulation in lysosomes as α-syn/LAMP2 colocalization area (E), autophagosomes as LC3b(+) vesicles per TH(+) neuron (F), autolysosomes as LC3b(+) vesicles colocalized with LAMP2 area in TH(+) neurons (G), and functional lysosomes expressed as area of PhenoVue 577(+) staining per SH-SY5Y cell (H), expressed as % of control (CTR). Raw values for CTR (i.e., 100%); sum TH(+) neurons per well, i.e., per biological replicate = 32 ± 1.3; neurite network = 1054 ± 60.6 µm; α-syn area/TH(+) neuron = 25.2 ± 2.8 µm 2 ; LAMP2 area/TH(+) neurons = 17.9 ± 1.5 µm 2 ; α-syn area/LAMP2/TH(+) neuron = 4.4 ± 0.3 µm 2 ; LC3b area/TH(+) neurons = 27 ± 1.7 µm 2 ; LAMP2/LC3b area/TH(+) neurons = 7.8 ± 0.5 µm 2 ; PhenoVue 577(+) staining/SH-SY5Y cell = 67 ± 3.5 µm 2 . Each bar represents the mean ± SEM, one-way ANOVA followed by Fisher’s test. ### p < 0.001 or #### p < 0.0001 from CTR; *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 from the α-syn condition, (n = 5-6).
Article Snippet:
Techniques: Analysis, Staining, Functional Assay, Control
Journal: PLOS One
Article Title: AZP2006 in Parkinson’s disease models: A promising new neuroprotective treatment involving lysosomal homeostasis and the Progranulin/Prosaposin complex
doi: 10.1371/journal.pone.0359269
Figure Lengend Snippet: ICC analysis of cultures shows the total number of TH(+) neurons (A) and the length of their neurite network neurons (B) and microglia activation as area of OX-41(+) staining (C), expressed as % of control. Raw values for control (CTR) (i.e., 100%); sum TH(+) neurons per well, i.e., per biological replicate = 81 ± 4.0; neurite network = 2332 ± 112 µm; OX-41(+) area/field = 1421 ± 67 µm 2 . Each bar represents the mean ± SEM, one-way ANOVA followed by Fisher’s test. ### p < 0.001 or #### p < 0.0001 from CTR; **p < 0.01, ***p < 0.001 and ****p < 0.0001 from α-syn injury, (n = 4-6 / group).
Article Snippet:
Techniques: Analysis, Activation Assay, Staining, Control
Journal: PLOS One
Article Title: AZP2006 in Parkinson’s disease models: A promising new neuroprotective treatment involving lysosomal homeostasis and the Progranulin/Prosaposin complex
doi: 10.1371/journal.pone.0359269
Figure Lengend Snippet: ICC analysis shows the total number of cells (A, D), the area of cytoplasmic α-syn staining per cell (B,E) and lysosomal burden as area of LAMP2(+) vesicles per cell (C,F), expressed as % of control (CTR = PGRN KO alone in D-F). Raw values for PGRN KO CTR (i.e., 100%); cells/image field = 140 ± 3.9; α-syn area/cell = 38.1 ± 2.8 µm 2 ; LAMP2(+) area/cell = 51 ± 2.8 µm 2 . Each bar represents the mean ± SEM, one-way ANOVA followed by Fisher’s test. ## p < 0.01 or #### p < 0.0001 from CTR and *p < 0.05, **p < 0.01; ***p < 0.001 or ****p < 0.0001 from MPP + (n = 4-6 / group).
Article Snippet:
Techniques: Analysis, Staining, Control
Journal: bioRxiv
Article Title: Decoding subtype development and function in human pluripotent stem cell-derived midbrain dopaminergic neurons
doi: 10.64898/2026.09.23.753784
Figure Lengend Snippet: a , Experimental schematic of TGFβ pathway modulation during mDA progenitor patterning. b, PITX3::GFP reporter design (top), flow cytometry of PITX3 CRISPRa activation (middle), and immunofluorescence (IF) for PITX3 and TH at D30 (bottom). c, Flow cytometry of PITX3, CD171 and CD99 at D25. d, Flow cytometry of ALDH activity and CD99 at D25. e, Flow cytometry of PITX3 expression and ALDH activity in the indicated gated subpopulations, with quantification of the percentage of PITX3+ALDH+ cells in each subpopulation. One-way ANOVA; n = 4. f, RT–qPCR of the indicated genes in D25 control and Activin A/BMP7-patterned populations. Student’s t -test; n = 3. g, Flow cytometry of PITX3 and ALDH activity in the indicated CD99-CD56+ populations. h, IF for PITX3, ALDH1A1 and CALB1 at D26. Scale bars, 100 μm. i, Schematic illustrating mDA subtype patterning through modulation of TGF-β signaling. j, Schematic of the day 25 sorting strategy and RT–qPCR analysis of the indicated genes in sorted day 25 populations. One-way ANOVA; n = 3–4. k, IF for ALDH1A1, PITX3 and CALB1 at D26 in populations derived from D25 sorted cells (left), with quantification of relative ALDH1A1 expression (right). Scale bars, 100 μm. One-way ANOVA; n = 4–8. l, Flow cytometry of TH and ALDH activity in the indicated CD99− and CD99+ populations, with quantification of the percentage of CD99-TH+ALDH+ cells. One-way ANOVA; n = 3. m . Schematic of hPSC-A9/A10 transplantation into the mouse striatum (top); IF staining for GIRK2, TH and CALB1 in A9 and A10 grafts at 6 months post-transplantation, with quantification of GIRK2+TH+ and CALB1+TH+ cells in the grafts. Student’s t -test; n = 3. All error bars in represent s.e.m.
Article Snippet: Sections were incubated overnight at 4 °C with primary
Techniques: Flow Cytometry, Activation Assay, Immunofluorescence, Activity Assay, Expressing, Quantitative RT-PCR, Control, Analysis, Derivative Assay, Transplantation Assay, Staining, FACS
Journal: bioRxiv
Article Title: Histone lysine demethylase inhibition is a disease-modifying therapy for hypertrophic cardiomyopathy
doi: 10.64898/2026.08.07.743611
Figure Lengend Snippet: (A) Volcano plots showing differentially expressed genes (DEGs) in HCM_veh versus non-HCM controls (left) and HCM_JIB-04 versus HCM_veh hearts (right). Each dot represents a single gene. Red dots indicate significantly upregulated or downregulated DEGs that meet the predefined statistical significance threshold, whereas green dots represent genes that do not meet the significance threshold. (B) Venn diagrams illustrating overlap between genes dysregulated in HCM and genes normalized by JIB-04 treatment. Upper panel, genes upregulated in HCM and downregulated by JIB-04; lower panel, genes downregulated in HCM and upregulated by JIB-04. (C) Gene Ontology (GO) biological process enrichment analysis of genes increased in HCM relative to non-HCM controls (top) and genes increased by JIB-04 treatment relative to vehicle-treated HCM hearts (bottom). (D) Heat maps showing representative genes from selected pathways altered in HCM and restored by JIB-04, including DAMP signaling, t-tubule/junctional pathways, PI3K/AKT signaling, Wnt signaling, PKG signaling, Spi1-associated cell fate, and fibrosis programs. (E) Relative expression of genes involved in inflammation and fibrosis in wild-tpe and HCM heart treated with vehicle or JIB-04. Data are presented as mean ± SD. *, P < 0.05. (F) Representative immunostaining for connexin-43 (Cx43, red), cardiomyocytes autofluoresence (green), and nuclei (DAPI, blue) in WT, HCM_veh, and HCM_JIB-04 hearts. Arrows indicate Cx43 localized at intercalated discs in WT and JIB-04 treated hearts. Arrowheads in HCM_veh hearts indicate lateralized and intracellular Cx43. JIB-04 restored Cx43 localization toward the WT pattern.
Article Snippet:
Techniques: Analysis, Expressing, Immunostaining, RNA Sequencing, Real-time Polymerase Chain Reaction, Immunofluorescence
Journal: bioRxiv
Article Title: Histone lysine demethylase inhibition is a disease-modifying therapy for hypertrophic cardiomyopathy
doi: 10.64898/2026.08.07.743611
Figure Lengend Snippet: Human MYH7 R403Q HCM iPSC-derived cardiomyocytes (HCM1) and isogenic gene-corrected control cardiomyocytes (HCM1 corr ) were treated with vehicle or JIB-04 and analyzed by molecular, structural, and metabolic assays. (A) Expression of the hypertrophic marker Ankrd1, fibrotic/injury marker Timp1, and metabolic regulator Pdk4 measured by qRT-PCR. (B) Immunofluorescence staining for connexin-43 (Cx43, green), cardiac troponin T (cTnT, red), and nuclei (DAPI, blue). (C-D) Seahorse extracellular flux analysis showing oxygen consumption rate (OCR; C) and extracellular acidification rate (ECAR; D). Oligomycin, FCCP, and rotenone/antimycin A were sequentially injected to assess ATP-linked respiration, maximal respiratory capacity, and non-mitochondrial respiration, respectively. JIB-04 normalized disease-associated gene expression, restored membrane localization of Cx43, and improved mitochondrial function in HCM1 cardiomyocytes with minimal effects in isogenic corrected controls. Data are presented as mean ± SD. n = 3 independent experiments for qRT-PCR and n = 10 wells per group for Seahorse analyses.
Article Snippet:
Techniques: Derivative Assay, Control, Expressing, Marker, Quantitative RT-PCR, Immunofluorescence, Staining, Analysis, Injection, Gene Expression, Membrane, XF Assay